Also indexed as: Arterial Disease, Coronary Artery Disease, Coronary Heart Disease, Hardening of the Arteries, Plaque (Arterial)
Get your blood flowing freely and protect your arteries from hardening with a few healthy habits. According to research or other evidence, the following self-care steps may be helpful:
These recommendations are not comprehensive and are not intended to replace the advice of your doctor or pharmacist. Continue reading the full atherosclerosis article for more in-depth, fully-referenced information on medicines, vitamins, herbs, and dietary and lifestyle changes that may be helpful.
Atherosclerosis is hardening of the arteries, a common disease of the major blood vessels characterized by fatty streaks along the vessel walls and by deposits of cholesterol and calcium.
Atherosclerosis of arteries supplying the heart is called coronary artery disease. It can restrict the flow of blood to the heart, which often triggers heart attacks—the leading cause of death in Americans and Europeans. Atherosclerosis of arteries supplying the legs causes a condition called intermittent claudication, which is characterized by pain in the legs after walking short distances.
People with elevated cholesterol levels are much more likely to have atherosclerosis than people with low cholesterol levels. Many important nutritional approaches to protecting against atherosclerosis are aimed at lowering serum cholesterol levels.
People with diabetes are also at very high risk for atherosclerosis, as are people with elevated triglycerides and high homocysteine.
Product ratings for atherosclercosis
|Science Ratings||Nutritional Supplements||Herbs|
Horny goat weed
Evening primrose oil
Lycopene (prevention only)
Peony (red peony root)
Shelled hemp seed
and relatively consistent scientific data showing a substantial health benefit.
Contradictory, insufficient, or preliminary studies suggesting a health benefit or minimal health benefit.
For an herb, supported by traditional use but minimal or no scientific evidence. For a supplement, little scientific support and/or minimal health benefit.
Atherosclerosis is typically a silent disease until one of the many late-stage vascular manifestations intervenes. Some people with atherosclerosis may experience angina (chest pain) or intermittent claudication (leg cramps and pain) on exertion. Symptoms such as these develop gradually as the disease progresses.
The most important dietary changes in protecting arteries from atherosclerosis include avoiding meat and dairy fat and avoiding foods that contain trans fatty acids (many margarines, some vegetable oils, and many processed foods containing vegetable oils). Increasingly, the importance of avoiding trans fatty acids is being accepted by the scientific community.1 Leading researchers have recently begun to view the evidence linking trans fatty acids to markers for heart disease as “unequivocal.”2
People who eat diets high in alpha-linolenic acid (ALA), which is found in canola oil and flaxseed products, have higher blood levels of omega-3 fatty acids than those consuming lower amounts,3 4 which may confer some protection against atherosclerosis. In 1994, researchers conducted a study in people with a history of heart disease, using what they called the “Mediterranean” diet.5 The diet differed significantly from what people from Mediterranean countries actually eat, in that it contained little olive oil. Instead, the diet included a special margarine high in ALA. Those people assigned to the Mediterranean diet had a remarkable 70% reduced risk of dying from heart disease compared with the control group during the first 27 months. Similar results were also confirmed after almost four years.6 The diet was high in beans and peas, fish, fruit, vegetables, bread, and cereals, and low in meat, dairy fat, and eggs. Although the authors believe that the high ALA content of the diet was partly responsible for the surprising outcome, other aspects of the diet may have been partly or even totally responsible for decreased death rates. Therefore, the success of the Mediterranean diet does not prove that ALA protects against heart disease.7
A systematic review of 20 years of research evaluated the association between dietary fiber and coronary heart disease.8 The meta-analysis portion of this review showed that whole grain foods are associated with a coronary heart disease risk reduction of about 26%. In general, the fibers most linked to the reduction of cholesterol levels are found in oats, psyllium seeds, fruit (pectin) and beans (guar gum).9 An analysis of many soluble fiber trials proves that a cholesterol lowering effect exists, but the amount the cholesterol falls is quite modest.10 For unknown reasons, however, diets higher in insoluble fiber (found in whole grains and vegetables and mostly unrelated to cholesterol levels) have been reported to correlate better with protection against heart disease in both men and women.11 12 Some trials have used 20 grams of additional fiber per day for several months to successfully lower cholesterol.13
Independent of their action on serum cholesterol, foods that contain high amounts of cholesterol—mostly egg yolks—can induce atherosclerosis.14 It makes sense to reduce the intake of egg yolks. However, eating eggs does not increase serum cholesterol as much as eating saturated fat, and eggs may not increase serum cholesterol at all if the overall diet is low in fat. A decrease in atherosclerosis resulting from a pure vegetarian diet (no meat, poultry, dairy or eggs), combined with exercise and stress reduction, has been proven by controlled medical research.15
Preliminary evidence has suggested that excessive salt consumption is a risk factor for heart disease and death from heart disease in overweight people.16 Controlled trials are needed to confirm these observations.
Eating a diet high in refined carbohydrates (e.g., white flour, white rice, simple sugars) appears to increase the risk of coronary heart disease, and thus of heart attacks, especially in overweight women.17 However, controlled trials of reducing refined carbohydrate intake to prevent heart disease have not been attempted to confirm these preliminary findings.
Virtually all doctors acknowledge the abundant evidence that smoking is directly linked to atherosclerosis and heart disease.18 Quitting smoking protects many people from atherosclerosis and heart disease, and is a critical step in the process of disease prevention.19 20
Obesity,21 type A behavior (time conscious, impatient, and aggressive), stress,22 and sedentary lifestyle23 are all associated with an increased risk of atherosclerosis; interventions designed to change these risk factors are linked to protection from this condition.24
Aggressive verbal or physical responses when angry have been consistently related to coronary atherosclerosis in numerous preliminary studies.25 26 27 A low level of social support, especially when combined with a high level of outwardly expressed anger has also been associated with accelerated progression of coronary atherosclerosis.28
Prevention is still the best treatment for atherosclerosis, which may be supported by drugs used to prevent high cholesterol, triglyceride, homosysteine, and blood glucose levels. Once established, treatment is directed toward the various complications, such as angina, heart attacks, heart failure, stroke, kidney failure, and peripheral vascular disease.
Tocotrienols may offer protection against atherosclerosis by preventing oxidative damage to LDL cholesterol.29 In a double-blind trial in people with severe atherosclerosis of the carotid artery—the main artery supplying blood to the head—tocotrienol administration (200 mg per day) reduced the level of lipid peroxides in the blood. Moreover, people receiving tocotrienols for 12 months had significantly more protection against atherosclerosis progression, and in some cases reductions in the size of their atherosclerotic plaques, compared with those taking a placebo.30
Supplementation with fish oil, rich in omega-3 fatty acids, has been associated with favorable changes in various risk factors for atherosclerosis and heart disease in some,31 32 33 34 35 36 but not all, studies.37 38 39 A double-blind trial showed that people with atherosclerosis who took fish oil (6 grams per day for 3 months and then 3 grams a day for 21 months) had significant regression of atherosclerotic plaques and a decrease in cardiovascular events (e.g., heart attack and stroke) compared with those who did not take fish oil.40 These results contradict the findings of an earlier controlled trial in which fish oil supplementation for two years (6 grams per day) did not promote major favorable changes in the diameter of atherosclerotic coronary arteries.41
In some studies, people who consumed more selenium in their diet had a lower risk of heart disease.42 43 In one double-blind report, people who had already had one heart attack were given 100 mcg of selenium per day or placebo for six months.44 At the end of the trial, there were four deaths from heart disease in the placebo group but none in the selenium group; however, the number of people was too small for this difference to be statistically significant. Some doctors recommend that people with atherosclerosis supplement with 100–200 mcg of selenium per day.
Experimentally increasing homocysteine levels in humans has led to temporary dysfunction of the cells lining blood vessels. Researchers are concerned this dysfunction may be linked to atherosclerosis and heart disease. Vitamin C has been reported in one controlled study to reverse the dysfunction caused by increases in homocysteine.45 Vitamin C also protects LDL.46
Despite the protective mechanisms attributed to vitamin C, some research has been unable to link vitamin C intake to protection against heart disease. These negative trials have mostly been conducted using people who consume 90 mg of vitamin C per day or more—a level beyond which further protection of LDL may not occur. Studies of people who eat foods containing lower amounts of vitamin C have been able to show a link between dietary vitamin C and protection from heart disease. Therefore, leading vitamin C researchers have begun to suggest that vitamin C may be important in preventing heart disease, but only up to 100–200 mg of intake per day.47 In a double-blind trial,48 supplementation with 250 mg of timed-release vitamin C twice daily for three years resulted in a 15% reduction in the progression of atherosclerosis, compared with placebo. Many doctors suggest that people take vitamin C—often 1 gram per day—despite the fact that research does not yet support levels higher than 500 mg per day.
Vitamin E is an antioxidant that serves to protect LDL from oxidative damage49 and has been linked to prevention of heart disease in double-blind research.50 Many doctors recommend 400–800 IU of vitamin E per day to lower the risk of atherosclerosis and heart attacks. However, some leading researchers suggest taking only 100–200 IU per day, as studies that have explored the long-term effects of different supplemental levels suggest no further benefit beyond that amount, and research reporting positive effects with 400–800 IU per day have not investigated the effects of lower intakes.51 In a double-blind trial, people with high cholesterol who took 136 IU of natural vitamin E per day for three years had 10% less progression of atherosclerosis compared with those taking placebo.52
Blood levels of an amino acid called homocysteine have been linked to atherosclerosis and heart disease in most research,53 54 though uncertainty remains about whether elevated homocysteine actually causes heart disease.55 56 Although some reports have found associations between homocysteine levels and dietary factors, such as coffee and protein intakes,57 evidence linking specific foods to homocysteine remains preliminary. Higher blood levels of vitamin B6, vitamin B12, and folic acid are associated with low levels of homocysteine58 and supplementing with these vitamins lowers homocysteine levels.59 60
While several trials have consistently shown that B6, B12, and folic acid lower homocysteine, the amounts used vary from study to study. Many doctors recommend 50 mg of vitamin B6, 100–300 mcg of vitamin B12, and 500–800 mcg of folic acid. Even researchers finding only inconsistent links between homocysteine and heart disease have acknowledged that a B vitamin might offer protection against heart disease independent of the homocysteine-lowering effect.61 In one trial, people with normal homocysteine levels had demonstrable reversal of atherosclerosis when supplementing B vitamins (2.5 mg folic acid, 25 mg vitamin B6, and 250 mcg of vitamin B12 per day).62 Similar results were seen in another study.63
For the few cases in which vitamin B6, vitamin B12, and folic acid fail to normalize homocysteine, adding 6 grams per day of betaine (trimethylglycine) may be effective.64 Of these four supplements, folic acid appears to be the most important.65 Attempts to lower homocysteine by simply changing the diet rather than by using vitamin supplements have not been successful.66
Quercetin, a flavonoid, protects LDL cholesterol from damage.67 While several preliminary studies have found that eating foods high in quercetin lowers the risk of heart disease,68 69 70 the research on this subject is not always consistent,71 and some research finds no protective link.72 Quercetin is found in apples, onions, black tea, and as a supplement. In some studies, dietary amounts linked to protection from heart disease are as low as 35 mg per day.
Though low levels (2 grams per day) of evening primrose oil appear to be without action,73 3–4 grams per day have lowered cholesterol in double-blind research.74 Lowering cholesterol levels should in turn reduce the risk of atherosclerosis.
Preliminary research shows that chondroitin sulfate may prevent atherosclerosis in animals and humans and may also prevent heart attacks in people who already have atherosclerosis.75 76 However, further research is needed to determine the value of chondroitin sulfate supplements for preventing or treating atherosclerosis.
Preliminary studies have found that people who drink red wine, which contains resveratrol, are at lower risk of death from heart disease. Because of its antioxidant activity and its effect on platelets, some researchers believe that resveratrol is the protective agent in red wine.77 78 79 Resveratrol research remains very preliminary, however, and as yet there is no evidence that the amounts found in supplements help prevent atherosclerosis in humans.
In 1992, a Finnish study found a strong link between unnecessary exposure to iron and increased risk for heart disease.80 Since then many studies have not found that link,81 82 83 though perhaps an equal number have been able to confirm the outcome of the original report.84 85 One 1999 analysis of 12 studies looking at iron status and heart disease found no overall relationship,86 though another 1999 analysis of published studies came to a different conclusion.87 While the effect of unnecessary exposure to iron, including iron supplements, on the risk of heart disease remains unclear, there is no benefit in supplementing iron in the absence of a diagnosed deficiency.
The carotenoid, lycopene, has been found to be low in the blood of people with atherosclerosis, particularly if they are smokers.88 Although no association between atherosclerosis and blood level of any other carotenoid (e.g., beta-carotene) was found, the results of this study suggested a protective role for lycopene. Lycopene is present in high amounts in tomatoes.
Are there any side effects or interactions?
Refer to the individual supplement for information about any side effects or interactions.
Many actions associated with herbal supplements may help prevent or potentially alleviate atherosclerosis. Herbs such as garlic and ginkgo appear to directly affect the hardened arteries by multiple mechanisms. Herbs such as psyllium, guggul, and fenugreek reduce cholesterol and other lipid levels in the blood—known risk factors for hardened arteries. A related group of herbs, including green tea, prevents the oxidation of cholesterol, an important step in protecting against atherosclerosis. In a preliminary study of people living in Japan, drinking more green tea was associated with a lower death rate from cardiovascular disease.89 Finally, there are herbs such as ginger and turmeric that reduce excessive stickiness of platelets, thereby reducing atherosclerosis.
|Fenugreek, garlic, guggul, psyllium||Cholesterol-lowering|
|Green tea||Block oxidation of cholesterol|
|Garlic, ginger, ginkgo, peony, turmeric||Decrease excessive platelet stickiness|
|Butcher’s broom, rosemary||Traditionally considered circulatory stimulant|
Garlic has been shown to prevent atherosclerosis in a four-year double-blind trial.90 The preparation used, standardized for 0.6% allicin content, provided 900 mg of garlic powder per day. The people in this trial were 50 to 80 years old, and the benefits were most notable in women. This trial points to the long-term benefits of garlic to both prevent and possibly slow the progression of atherosclerosis in people at risk.
Garlic has also lowered cholesterol levels in double-blind research,91 though more recently, some double-blind trials have not found garlic to be effective.92 93 94 Some of the negative trials have flaws in their design.95 Nonetheless, the relationship between garlic and cholesterol-lowering is somewhat unclear.96
Garlic has also been shown to prevent excessive platelet adhesion (stickiness) in humans.97 Allicin, often considered the main active component of garlic, is not alone in this action. The constituent known as ajoene has also shown beneficial effects on platelets.98 Aged garlic extract, but not raw garlic, has been shown, to prevent oxidation of LDL cholesterol in humans,99 an event believed to be a significant factor in the development of atherosclerosis.
Ginkgo may reduce the risk of atherosclerosis by interfering with a chemical the body sometimes makes in excess, called platelet activating factor (PAF).100 PAF stimulates platelets to stick together too much; ginkgo stops this from happening. Ginkgo also increases blood circulation to the brain, arms, and legs.101
Garlic and ginkgo also decrease excessive blood coagulation. Both have been shown in double-blind102 and other controlled103 trials to decrease the overactive coagulation of blood that may contribute to atherosclerosis.
Guggul has been less extensively studied, but double-blind evidence suggests it can significantly improve cholesterol and triglyceride levels in people.104 Numerous medicinal plants and plant compounds have demonstrated an ability to protect LDL cholesterol from being damaged by free radicals. Garlic,105 ginkgo,106 and guggul107 are of particular note in this regard. Garlic and ginkgo have been most convincingly shown to protect LDL cholesterol in humans.
Horny goat weed has historically been used in people with symptoms caused by hardening of the arteries, in particular those recovering from strokes. One study of older people who had symptoms due to hardening neck arteries found that a formula in which the main ingredient was horny goat weed was superior to one not containing horny goat weed at relieving symptoms and improving the electrocardiogram findings.108
Several other herbs have been shown in research to lower lipid levels. Of these, psyllium has the most consistent backing from multiple double-blind trials showing lower cholesterol and triglyceride levels.109 The evidence supporting the ability of fenugreek to lower lipid levels is not as convincing, coming from preliminary studies only.110
Since oxidation of LDL cholesterol is thought to be important in causing or accelerating atherosclerosis, and green tea protects against oxidation, this herb may have a role in preventing atherosclerosis. However, while some studies show that green tea is an antioxidant in humans,111 others have not been able to confirm that it protects LDL cholesterol from damage.112 Much of the research documenting the health benefits of green tea is based on the amount of green tea typically drunk in Asian countries—about three cups per day (providing 240–320 mg of polyphenols).
The research on ginger’s ability to reduce platelet stickiness indicates that 10 grams (approximately 1 heaping teaspoon) per day is the minimum necessary amount to be effective.113 Lower amounts of dry ginger,114 as well as various levels of fresh ginger,115 have not been shown to affect platelets.
Turmeric’s active compound curcumin has shown potent anti-platelet activity in animal studies.116 It has also demonstrated this effect in preliminary human studies.117 In a similar vein, bilberry has been shown to prevent platelet aggregation118 as has peony.119 However, none of these three herbs has been documented to help atherosclerosis in human trials.
Butcher’s broom and rosemary are not well studied as being circulatory stimulants but are traditionally reputed to have such an action that might impact atherosclerosis. While butcher’s broom is useful for various diseases of veins, it also exerts effects that are protective for arteries.120
Though it has not been studied, shelled hemp seed or its oil may theoretically be useful for people with atherosclerosis due to its content of essential fatty acids.121
Are there any side effects or interactions?
Refer to the individual herb for information about any side effects or interactions.
1. Nelson GJ. Dietary fat, trans fatty acids, and risk of coronary heart disease. Nutr Rev 1998;250–2.
2. Ascherio A, Willett WC. Health effects of trans fatty acids. Am J Clin Nutr 1997;66(suppl):1006S–10S [review].
3. Li D, Sinclair A, Wilson A, et al. Effect of dietary alpha-linolenic acid on thrombotic risk factors in vegetarian men. Am J Clin Nutr 1999;69:872–82.
4. Cunnane SC, Hamadeh MJ, Liede AC, et al. Nutritional attributes of traditional flaxseed in healthy young adults. Am J Clin Nutr 1994;61:62–8.
5. De Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic-rich diet in secondary prevention of coronary heart disease. Lancet 1994;343:1454–9.
6. De Lorgeril M, Salen P, Martin J-L, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon Diet Heart Study. Circulation 1999;99:779–85.
7. Rice RD. Mediterranean diet. Lancet 1994;344:893–4 [letter].
8. Anderson JW, Hanna TJ, Peng X, Kryscio RJ. Whole grain foods and heart disease risk. J Am Coll Nutr 2000;19(3 Suppl):291S–299S.
9. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999;69:30–42.
10. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999;69:30–42.
11. Jenkins DJA, Kendall CWC, Ransom TPP. Dietary fiber, the evolution of the human diet and coronary heart disease. Nutr Res 1998;18:633–52 [review].
12. Wolk A, Manson JE, Stampfer MJ, et al. Long-term intake of dietary fiber and decreased risk of coronary hart disease among women. JAMA 1999;281:1998–2004.
13. Knopp RH, Superko HR, Davidson M, et al. Long-term blood cholesterol-lowering effects of a dietary fiber supplement. Am J Prev Med 1999;17:18–23.
14. Raloff J. Oxidized lipids: a key to heart disease? Sci News 1985;127:278.
15. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? Lancet 1990;336:129–33.
16. He J, Ogden LG, Vupputuri S, et al. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA 1999;282:2027–34.
17. Liu S, Willett WC, Stampfer MJ, et al. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr 2000;71:1455–61.
18. Michael Pittilo R. Cigarette smoking, endothelial injury and cardiovascular disease. Int J Exp Pathol 2000;81:219–30 [review].
19. Wilson K, Gibson N, Willan A, Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000;160:939–44 [review].
20. Nyboe J, Jensen G, Appleyard M, Schnohr P. Smoking and the risk of first acute myocardial infarction. Am Heart J 1991;122:438.
21. Abate N. Obesity and cardiovascular disease. Pathogenetic role of the metabolic syndrome and therapeutic implications. J Diabetes Complications 2000;14:154–74 [review].
22. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999;99:2192–217 [review].
23. Gabriel HH, Heine G, Kroger K, et al. Exercise and atherogenesis: where is the missing link? Exerc Immunol Rev 1999;5:96–102 [review].
24. Sebregts EH, Falger PR, Bar FW. Risk factor modification through nonpharmacological interventions in patients with coronary heart disease. J Psychosom Res 2000;48:425–41 [review].
25. Miller TQ, Smith TW, Turner CW, et al. A meta-analytic review of research on hostility and physical health. Psychol Bull 1996;119:322–48.
26. Kawachi I, Sparrow D, Spiro A 3rd, et al. A prospective study of anger and coronary heart disease. The Normative Aging Study. Circulation 1996;94:2090–5.
27. Thomas SA, Friedmann E, Wimbush F, Schron E. Psychological factors and survival in the cardiac arrhythmia suppression trial (CAST): a reexamination. Am J Crit Care 1997;6:116–26.
28. Angerer P, Siebert U, Kothny W, et al. Impact of social support, cynical hostility and anger expression on progression of coronary atherosclerosis. J Am Coll Cardiol 2000;36:1781–8.
29. Suarna C, Hood RL, Dean RT, Stocker R. Comparative antioxidant activity of tocotrienols and other natural lipid-soluble antioxidants in a homogeneous system, and in rat and human lipoproteins. Biochim Biophys Acta 1993;1166:163–70.
30. Tomeo AC, Geller M, Watkins TR, et al. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Lipids 1995;30:1179–83.
31. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 1999;10:2177–84.
32. Olszewski AJ, McCully KS. Fish oil decreases serum homocysteine in hyperlipemic men. Coron Artery Dis 1993;4:53–60.
33. Phillipson BE, Rothrock DW, Connor WE, et al. Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med 1985;312:1210–6.
34. Haglund O, Wallin R, Luostarinen R, Saldeen T. Effects of a new fluid fish oil concentrate, ESKIMO-3, on triglycerides, cholesterol, fibrinogen and blood pressure. J Intern Med 1990;227:347–53.
35. Haglund O, Luostarinen R, Wallin W, Saldeen T. Effects of fish oil on triglycerides, lipoprotein(a), atherogenic index and fibrinogen. Influence of the degree of purification of the oil. Nutr Res 1992;12:455–68.
36. Haglund O, Luostarinen R, Wallin R, et al. The effects of fish oil on triglycerides, cholesterol, fibrinogen and malondialdehyde in humans supplemented with vitamin E. J Nutr 1991;121:165–9.
37. Leng GC, Lee AJ, Fowkes FG, et al. Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease. Clin Nutr 1998;17:265–71.
38. Leaf A, Jorgensen MB, Jacobs AK, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation 1994;90:2248–57.
39. Sacks FM, Stone PH, Gibson CM, et al. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. J Am Coll Cardiol 1995;25:1492–8.
40. von Schacky C, Angerer P, Kothny W, et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;130:554–62.
41. Sacks FM, Stone PH, Gibson CM, et al. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. J Am Coll Cardiol 1995;25:1492–8.
42. Salonen JT et al. Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. Lancet 1982;ii:175.
43. Shamberger RJ, Willis CE. Epidemiological studies on selenium and heart disease. Fed Proc 1976;35:578 [abstract #2061].
44. Korpela H, Kumpulainen J, Jussila E, et al. Effect of selenium supplementation after acute myocardial infarction. Res Comm Chem Pathol Pharmacol 1989; 65:249–52.
45. Chambers JC, McGregor A, Jean-Marie J, et al. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia. An effect reversible with vitamin C therapy. Circulation 1999;99:1156–60.
46. Frei B. Ascorbic acid protects lipids in human plasma and low-density lipoprotein against oxidative damage. Am J Clin Nutr 1991;54:1113S–8S.
47. Balz F. Antioxidant Vitamins and Heart Disease. Presented at the 60th Annual Biology Colloquium, Oregon State University, February 25, 1999.
48. Salonen JT, Nyyssönen K, Salonen R, et al. Antioxidant supplementation in atherosclerosis prevention (ASAP) study: a randomized trial of the effect of vitamin E and C on 3-year progression of carotid atherosclerosis. J Intern Med 2000;248:177–86.
49. Belcher JD, Balla J, Balla G, et al. Vitamin E, LDL, and endothelium: Brief oral vitamin supplementation prevents oxidized LDL-mediated vascular injury in vitro. Arterioscler Thromb 1993;13:1779–89.
50. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781–6.
51. Rimm E. Micronutrients, Coronary Heart disease and cancer: Should we all be on supplements? Presented at the 60th Annual Biology Colloquium, Oregon State University, February 25, 1999.
52. Salonen JT, Nyyssönen K, Salonen R, et al. Antioxidant supplementation in atherosclerosis prevention (ASAP) study: a randomized trial of the effect of vitamin E and C on 3-year progression of carotid atherosclerosis. J Intern Med 2000;248:177–86.
53. Stampfer MJ, Malinow R, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877–81.
54. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiobascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999;159:1077–80.
55. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. Circulation 1998;98:204–10.
56. Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease. Circulation 1998;98:196–9 [editorial/review].
57. Stolzen berg-Solomon RZ, Miller ER III, Maguire MG, et al. Association of dietary protein intake and coffee consumption with serum homocysteine concentrations in an older population. Am J Clin Nutr 1999;69:467–75.
58. Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693–8.
59. Ubbink JB, Hayward WJ, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927–33.
60. Manson JB, Miller JW. The effects of vitamin B12, B6, and folate on blood homocysteine levels. Ann NY Acad Sci 1992;669:197–204 [review].
61. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. Circulation 1998;98:204–10.
62. Hackam DG, Peterson JC, Spence JD. What level of plasma homocyst(e)ine should be treated? Am J Hypertens 2000;13:105–10.
63. Till U, Rohl P, Jentsch A, et al. Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, vitamins B6 and B12. Atherosclerosis 2005;181:131–5.
64. Franken DG, Boers GHJ, Blom HJ, et al. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994;14:465–70.
65. Ubbink JB, Vermaak WJH, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927–33.
66. Ubbink JB, van der Merwe A, Vermaak WJH, Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Investig 1993;71:993–8.
67. Ronzio RA. Antioxidants, nutraceuticals and functional foods. Townsend Letter for Doctors and Patients 1996;Oct:34–5 [review].
68. Hertog MGL, Feskens EJM, Hollman PCH, et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007–11.
69. Hertog MGL, Kromhout D, Aravanis C, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the Seven Countries Study. Arch Intern Med 1995;155:381–6.
70. Knekt P, Jarvinen R, Reunanen A, Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ 1996;312:478–81.
71. Rimm EB, Katan MB, Ascherio A, et al. Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Ann Intern Med 1996; 125:384–9.
72. Hertog MGL, Sweetnam PM, Fehily AM, et al. Antioxidant flavonols and ischemic heart disease in a Welsh population of men: the Caerphilly Study. Am J Clin Nutr 1997;65:1489–94.
73. Boberg M, Vessby B, Selinus I. Effects of dietary supplementation with n-6 and n-3 long-chain polyunsaturated fatty acids on serum lipoproteins and platelet function in hypertriglcyeridaemic patients. Acta Med Scand 1986;220:153–60.
74. Horrobin DF, Manku MS. How do polyunsaturated fatty acids lower plasma cholesterol levels? Lipids 1983;558–62.
75. Morrison LM, Branwood AW, Ershoff BH, et al. The prevention of coronary arteriosclerotic heart disease with chondroitin sulfate A: Preliminary report. Exp Med Surg 1969;27:278–89.
76. Morrison LM, Enrick NL. Coronary heart disease: Reduction of death rate by chondroitin sulfate A. Angiology 1973;24:269–82.
77. Bertelli AA, Giovanninni L, Bernini W, et al. Antiplatelet activity of cis-resveratrol. Drugs Exp Clin Res 1996;22(2):61–3.
78. Chen CK, Pace-Asciak. CR. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharm 1996;27(2):363–6.
79. Pace-Asciak CR, Rounova O, Hahn SE, et al. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 1996;246(1–2):163–82.
80. Salonen JT, Nyssönen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men.Circulation 1992;86:803–11.
81. Van Asperen IA, Feskens EJM, Bowles CH, Kromhout D. Body iron stores and mortality due to cancer and ischaemic heart disease: a 17-year follow-up study of elderly men and women. Int J Epidemiol 1995;24:665–70.
82. Iribarren C, Sempos CT, Eckfeldt JH, Folsom AR. Lack of association between ferritin level and measures of LDL oxidation: the ARIC study. Atherosclerosis 1998;139:189–95.
83. Corti M-C, Guralnik JM, Salive ME, et al. Serum iron level, coronary artery disease, and all-cause mortality in older men and women. Am J Cardiol 1997;79:120–7.
84. Tzonou A, Lagiou P, Trichopoulou A, et al. Dietary iron and coronary heart disease risk: a study from Greece. Am J Epidemiol 1998;147:161–6.
85. Kiechl S, Willeit J, Egger G, et al. Body iron stores and the risk of carotid atherosclerosis. Circulation 1997;96:3300–7.
86. Danesh J, Appleby P. Coronary heart disease and iron status. Meta-analyses of prospective studies. Circulation 1999;99:852–4.
87. de Valk B, Marx MMJ. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med 1999;159:1542–8 [review].
88. Klipstein-Grobusch K, Launer LJ, Geleijnse JM, et al. Serum carotenoids and atherosclerosis. The Rotterdam Study. Atherosclerosis 2000;148:49–56.
89. Kuriyama S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan. The Ohsaki Study. JAMA 2006;296:1255–65.
90. Koscienlny J, Klüßendorf D, Latza R, et al. The anti-atherosclerotic effect of Allium sativum. Atherosclerosis 1999;144:237–49.
91. Neil HAW, Silagy CA, Lancaster T, et al. Garlic powder in the treatment of moderate hyperlipidaemia: A controlled trial and a meta-analysis. J R Coll Phys 1996;30:329–34.
92. McCrindle BW, Helden E, Conner WT. Garlic extract therapy in children with hypercholesterolemia. Arch Pediatr Adolesc Med 1998;152:1089–94.
93. Isaacsohn JL, Moser M, Stein EA, et al. Garlic powder and plasma lipids and lipoproteins. Arch Intern Med 1998;158:1189–94.
94. Berthold HK, Sudhop T, von Bergmann K. Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism. JAMA 1998;279:1900–2.
95. Lawson L. Garlic oil for hypercholesterolemia–negative results. Quart Rev Natural Med 1998;Fall:185–6.
96. Garlic powder for hyperlipidemia–analysis of recent negative results. Quart Rev Natural Med 1998;Fall:187–9.
97. Kiesewetter H, Jung F, Pindur G, et al. Effect of garlic on thrombocyte aggregation, microcirculation and other risk factors. Int J Pharm Ther Toxicol 1991;29(4):151–5.
98. Srivastava KC, Tyagi OD. Effect of a garlic derived principle (ajoene) on aggregation and arachidonic acid metabolism in human blood platelets. Prostagl Leukotr Ess Fatty Acids 1993;49:587–95.
99. Munday JS, James KA, Fray LM, et al. Daily supplementation with aged garlic extract, but not raw garlic, protects low density lipoprotein against in vitro oxidation. Atherosclerosis 1999;143:399–404.
100. Braquet P, Touqui L, Shen TS, Vargaftig BB. Perspectives in platelet activating factor research. Pharmacol Rev 1987;39:97–210.
101. Brown DJ. Herbal Prescriptions for Better Health. Rocklin, CA: Prima Publishing, 1996, 119–28.
102. Kiesewetter H, Jung F, Mrowietz C, et al. Effects of garlic on blood fluidity and fibrinolytic activity: A randomised, placebo-controlled, double-blind study. Br J Clin Pract Suppl 1990;69:24–9.
103. Jung F, Mrowietz C, Kiesewetter H, Wenzel E. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers. Arzneimittelforschung 1990;40:589–93.
104. Brown D, Austin S. Hyperlipidemia and Prevention of Coronary Heart Disease. Seattle: Natural Product Research Consultants, 1997, 4–6.
105. Phelps S, Harris WS. Garlic supplementation and lipoprotein oxidation susceptibility. Lipids 1993;28(5):475–7.
106. Yan LJ, Droy-Lefaix MT, Packer L. Ginkgo biloba extract (EGb 761) protects human low density lipoproteins against oxidative modification mediated by copper. Biochem Biophys Res Comm 1995;212:360–6.
107. Singh K, Chander R, Kapoor NK. Guggulsterone, a potent hypolipidaemic, prevents oxidation of low density lipoprotein. Phytother Res 1997;11:291–4.
108. Tan X, Weng W. Efficacy of epimedium compound pills in the treatment of the aged patients with kidney deficiency syndrome of ischemic cardio-cerebral vascular diseases. Hunan Yi Ke Da Xue Xue Bao 1998;23:450–2 [in Chinese].
109. Olson BH, Anderson SM, Becker MP, et al. Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: Results of a meta-analysis. J Nutr 1997;127:1973–80.
110. Sharma RD, Raghuram TC, Dayasagar Rao V. Hypolipidaemic effect of fenugreek seeds. A clinical study. Phytother Res 1991;5:145–7.
111. Serafini M, Ghiselli A, Ferro-Luzzi A. In vivo antioxidant effect of green tea in man. Eur J Clin Nutr 1996;50:28–32.
112. van het Hof KH, de Boer HS, Wiseman SA, et al. Consumption of green or black tea does not increase resistance of low-density lipoprotein to oxidation in humans. Am J Clin Nutr 1997;66:1125–32.
113. Bordia A, Verma SK, Srivastava KC. Effect of ginger (Zingiber officinale Rosc) and fenugreek (Trigonella foenumgraceum L) on blood lipids, blood sugar, and platelet aggregation in patients with coronary artery disease. Prostagland Leukotrienes Essential Fatty Acids 1997;56:379–84.
114. Lumb AB. Effect of dried ginger on human platelet function. Thromb Haemost 1994;7:110–1.
115. Janssen PL, Meyboom S, van Staveren WA, et al. Consumption of ginger (Zingiber officinale Roscoe) does not affect ex vivo platelet thromboxane production in humans. Eur J Clin Nutr 1996;50:772–4.
116. Srivastava R, Dikshit M, Srimal RC, Dhawan BN. Anti-thrombotic action of curcumin. Throm Res 1985;404:413–7.
117. Srivastava KC, Bordia A, Verma SK. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prost Leuk Essen Fat Acids. 1995;52:223–7.
118. Pulliero G, Montin S, et al. Ex vivo study of the inhibitory effects of Vaccinium myrtillus (bilberry) anthocyanosides on human platelet aggregation. Fitoterapia 1989;60:69–75.
119. Liu J. Effect of Paeonia obovata 801 on metabolism of thromboxane B2 and arachidonic acid and on platelet aggregation in patients with coronary heart disease and cerebral thrombosis. Chin Med J 1983;63:477–81 [in Chinese].
120. Felix W, Schmidt Y, Nieberle J. Protective effect of Ruscus extract against injury of vascular endothelium and vascular smooth muscle caused by ethracrynic acid. Int Angiol 1983;3:77.
121. Fitzsimmons S. Hemp seed oil: Fountain of youth? Br J Phytother 1998;5:90–6.
Copyright © 2007 Healthnotes, Inc. All rights reserved. www.healthnotes.com
Learn more about Healthnotes, the company.
Learn more about the authors of Healthnotes.
The information presented in Healthnotes is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires September 2008.